2,7-bis(azepan-1-ylsulfonyl)anthracene-9,10-dione | 1083159-25-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 2,7-bis(azepan-1-ylsulfonyl)anthracene-9,10-dione
• CAS: 1083159-25-4
• 化学式: C₂₆H₃₀N₂O₆S₂
• 分子量: 530.666
• InChiKey: HMPBUVIMNZKIMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  126
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2,7-bis(azepan-1-ylsulfonyl)anthracene-9,10-dione 在 吡啶 、 盐酸羟胺 作用下， 反应 36.0h， 以64.3%的产率得到22,7-bis(azepan-1-ylsulfonyl)anthracene-9,10-dione dioxime
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors

  摘要：

  The Wnt/beta-catenin signaling pathway plays a vital role in cell growth, the regulation, cell development, and the differentiation of normal stem cells. Constitutive activation of the Wnt/beta-catenin signaling pathway is found in many human cancers, and thus, it is an attractive target for anticancer therapy. Specific inhibitors of this pathway have been keenly researched and developed. Cell based screening of compounds library, hit-to-lead optimization, computational and structurebased design strategies resulted in the design and synthesis of a series of anthracene-9,10-dione dioxime series of compounds demonstrated potent inhibition of beta-catenin in vitro (IC50 < 10 nM, 14) and the growth of several cancer cell lines. This article discusses the potential of inhibiting the Wnt/beta-catenin signaling pathway as a therapeutic approach for cancer along with an overview of the development of specific inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b00460
• 作为产物：
  描述：

  环己亚胺 、 9,10-dioxo-9,10-dihydroanthracene-2,7-disulfonyl dichloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 2,7-bis(azepan-1-ylsulfonyl)anthracene-9,10-dione
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors

  摘要：

  The Wnt/beta-catenin signaling pathway plays a vital role in cell growth, the regulation, cell development, and the differentiation of normal stem cells. Constitutive activation of the Wnt/beta-catenin signaling pathway is found in many human cancers, and thus, it is an attractive target for anticancer therapy. Specific inhibitors of this pathway have been keenly researched and developed. Cell based screening of compounds library, hit-to-lead optimization, computational and structurebased design strategies resulted in the design and synthesis of a series of anthracene-9,10-dione dioxime series of compounds demonstrated potent inhibition of beta-catenin in vitro (IC50 < 10 nM, 14) and the growth of several cancer cell lines. This article discusses the potential of inhibiting the Wnt/beta-catenin signaling pathway as a therapeutic approach for cancer along with an overview of the development of specific inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b00460

文献信息

• [EN] ANTHRAQUINONE DIOXIMES AND USES THEREOF<br/>[FR] DIOXIMES D'ANTHRAQUINONE ET LEURS UTILISATIONS
  申请人：AVALON PHARMACEUTICALS

  公开号：WO2010059142A1

  公开（公告）日：2010-05-27

  Anthraquinone dioximes and their derivatives are disclosed for use in treatment of diseases, especially cancer, such as colon and colorectal cancer. Methods of preparing such derivatives are also presented. Compositions of these compounds, as well as metabolites of said compounds and their use in gene modulation are also described.

  Anthraquinone dioximes 及其衍生物被揭示用于治疗疾病，特别是癌症，如结肠和结直肠癌。还介绍了制备这些衍生物的方法。同时，还描述了这些化合物的组成，以及其代谢物和在基因调控中的使用。
• Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors
  作者：Raffaella Soldi、Stephen K. Horrigan、Marek W. Cholody、Janak Padia、Venkataswamy Sorna、Jared Bearss、Glynn Gilcrease、Kapil Bhalla、Anupam Verma、Hariprasad Vankayalapati、Sunil Sharma

  DOI：10.1021/acs.jmedchem.5b00460

  日期：2015.8.13

  The Wnt/beta-catenin signaling pathway plays a vital role in cell growth, the regulation, cell development, and the differentiation of normal stem cells. Constitutive activation of the Wnt/beta-catenin signaling pathway is found in many human cancers, and thus, it is an attractive target for anticancer therapy. Specific inhibitors of this pathway have been keenly researched and developed. Cell based screening of compounds library, hit-to-lead optimization, computational and structurebased design strategies resulted in the design and synthesis of a series of anthracene-9,10-dione dioxime series of compounds demonstrated potent inhibition of beta-catenin in vitro (IC50 < 10 nM, 14) and the growth of several cancer cell lines. This article discusses the potential of inhibiting the Wnt/beta-catenin signaling pathway as a therapeutic approach for cancer along with an overview of the development of specific inhibitors.